OPTI Optimi Health Corp.

Optimi Health (OPTI.CN) said Wednesday it completed a production batch of 5-mg naturally derived psi

Key Takeaways; Psychedelic Sector Optimi Health Plans to Initiate Phase 3 Clinical Trial Evaluating MDMA Therapy for Individuals with PTSD Eli Lilly Completed $2.8 Billion Acquisition of AtaiBeckley, Expanding its Mental Health Pipeline Definium’s Phase 3 Panorama Trial Delivered Positive Results for DT120 in Generalized Anxiety Disorder Psyence BioMed Established Texas Entity to Advance U.S. […]

Shares of Optimi Health Corp. and other commercial manufacturers of MDMA and psilocybin are in focus, following federal administrative actions, a public hearing on psychedelic medicines, and an old endorsement of these drugs by tech billionaire Elon Musk. Optimi Health...

Biotech stocks can offer high reward opportunities. Here are three North American biotech stocks that could offer both growth and value.

Rising rates are squeezing indebted businesses. Meet three small cap stocks with strong revenue growth and low debt, plus a screener to find more like them.

Key Takeaways; Cannabis Sector Aurora Cannabis Urged Shareholders to Reject Curaleaf’s Hostile Takeover Bid Tilray Expanded Global Cannabis Production as International Medical Demand Continues to Grow Key Takeaways; Psychedelic Sector Jupiter Neurosciences Raised $2 Million as the Company Advances its Parkinson’s Drug Program Optimi Health Secured Discretionary Equity Facility as Psychedelic Drug Business Expands SciSparc […]

Psychedelics stocks are becoming more popular as more research goes into them. Here are 3 stock ideas for your watchlist.

Optimi Health has added financial flexibility to its growth strategy as it advances its MDMA and psilocybin business.

Key Takeaways; Cannabis Sector Curaleaf Holdings Announced Intention to Launch a Hostile Takeover Bid to Acquire Aurora Cannabis Organigram Posted Record Quarter as Sanity Group Acquisition Fueled Global Expansion Key Takeaways; Psychedelic Sector Optimi Health Set Up US$100 Million Equity Facility to Support Growth Definium Therapeutics’ Phase 3 Trial Delivered Strong Results for DT120 in […]

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground Cronos Group Reported Record Q2 Revenue as Profitability and EBITDA Surged Key Takeaways; Psychedelic Sector Compass Pathways is Building Momentum Toward Potential COMP360 Launch as Veterans […]

Big pharma is funding a field it once dismissed. These three psychedelic stocks carry possible clinical catalysts as the healthcare industry turns to alternative medicines.

Key Takeaways; Cannabis Sector Tilray Brands Expanded Medical Cannabis Platform with HelloMD Acquisition Vireo Growth Entered Pennsylvania with $20 Million Retail License Deal Key Takeaways; Psychedelic Sector Optimi Health Shipped Third Commercial Psilocybin Export to Australia Helus Pharma Reported Wider Fiscal Year 2026 Loss as Lead Depression Drug Advances Toward Phase 3 Readout Clearmind Medicine […]